First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)-Reference-Cited by-同舟云学术

First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)

Published:2023-06 Issue:6 Volume:34 Page:520-530
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Spreafico A.,Heirali A.A.,Araujo D.V.,Tan T.J.,Oliva M.,Schneeberger P.H.H.,Chen B.,Wong M.K.,Stayner L.-A.,Hansen A.R.,Saibil S.D.,Wang B.X.,Cochrane K.,Sherriff K.,Allen-Vercoe E.,Xu W.,Siu L.L.,Coburn B.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference24 articles.

1. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients;Matson;Science,2018

2. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients;Gopalakrishnan;Science,2018

3. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors;Routy;Science,2018

4. The microbiome, cancer, and cancer therapy;Helmink;Nat Med,2019

5. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients;Davar;Science,2021

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacomicrobiomics in precision cancer therapy: bench to bedside;Frontiers in Immunology;2024-09-09

2. Fecal microbiota transplantation promotes immunotherapy sensitivity in refractory gastrointestinal cancer patients: open label, single-arm, single center, phase 1 study;2024-08-21

3. The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect;Cancer Letters;2024-08

4. Pangenomic analysis identifies correlations between Akkermansia species and subspecies and human health outcomes;Microbiome Research Reports;2024-06-11

5. Exploiting bacteria for cancer immunotherapy;Nature Reviews Clinical Oncology;2024-06-05